Related Experiment Video
Updated: Oct 25, 2025

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
The Role of Co-Signaling Molecules in Psoriasis and Their Implications for Targeted Treatment
Suqing Liu1, Jinhua Xu1, Jinfeng Wu1
1Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Abstract:
Psoriasis is a chronic, systemic immune-mediated inflammatory disease manifesting in the skin, joint or both. Co-signaling molecules are essential for determining the magnitude of the T cell response to the antigen. According to the function of co-signaling molecules, they can be divided into co-stimulatory molecules and co-inhibitory molecules. The role of co-signaling molecules in psoriasis is recognized, mainly including the co-stimulatory molecules CD28, CD40, OX40, CD27, DR3, LFA-1, and LFA-3 and the co-inhibitory molecules CTLA-4, PD-1, and TIM-3. They impact the pathological process of psoriasis by modulating the immune strength of T cells, regulating the production of cytokines or the differentiation of Tregs. In recent years, immunotherapies targeting co-signaling molecules have made significant progress and shown broad application prospects in psoriasis. This review aims to outline the possible role of co-signaling molecules in the pathogenesis of psoriasis and their potential application for the treatment of psoriasis.
Insights
Co-signaling molecules regulate T cell responses in psoriasis. Targeting these molecules offers promising new immunotherapies for this chronic inflammatory disease.
Area of Science:
- Immunology
- Dermatology
- Inflammation Research
Background:
- Psoriasis is a chronic, systemic immune-mediated inflammatory disease affecting skin and joints.
- Co-signaling molecules are crucial for T cell response magnitude and function.
- These molecules are categorized as co-stimulatory (e.g., CD28, CD40) and co-inhibitory (e.g., CTLA-4, PD-1).
Purpose of the Study:
- To review the role of co-signaling molecules in psoriasis pathogenesis.
- To explore the therapeutic potential of targeting co-signaling molecules for psoriasis treatment.
Main Methods:
- Literature review of co-signaling molecules in psoriasis.
- Analysis of molecular mechanisms in immune modulation.
- Evaluation of current and emerging immunotherapies.
Main Results:
- Co-signaling molecules (CD28, CD40, OX40, CD27, DR3, LFA-1, LFA-3, CTLA-4, PD-1, TIM-3) significantly impact psoriasis.
- These molecules modulate T cell immunity, cytokine production, and Treg differentiation.
- Immunotherapies targeting co-signaling molecules show significant progress.
Conclusions:
- Co-signaling molecules are key players in the immune pathogenesis of psoriasis.
- Targeting co-signaling pathways presents a promising therapeutic strategy for psoriasis management.
More Related Videos
Related Concept Videos
The JAK-STAT Signaling Pathway
Types of Signaling Molecules
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Paracrine Signaling
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...

